Tact.ai
Now part of PharmaForceIQ | Intelligent Customer Engagement for Life Sciences Teams
Est 2008|Valuation $150M|Raised $203.8M
Now part of PharmaForceIQ | Intelligent Customer Engagement for Life Sciences Teams
Published Jul 14, 2026
Not clearly available in accessible official sources for Tact.ai. Aktana has indicated intent to enhance Copilot capabilities for specific use cases following the acquisition, but detailed roadmap commitments are not available in the accessible excerpts.
A practical limitation is product identity ambiguity:
Common reasons suggested by G2 and TechCrunch coverage:
Direct, product-specific community discussions about Tact.ai were hard to locate in accessible searches; many Reddit results for “tact” refer to unrelated products or generic discussions about AI sales assistants. Hacker News results for Tact.ai were not surfaced in accessible search results, likely due to naming ambiguity and the relative age of older coverage.
Direct churn reasons are not explicitly documented in accessible customer sources, but plausible drivers include:
A “Tact Pharma Success Story” PDF is accessible, but details in the excerpt are limited. Vendor case studies typically highlight outcomes (productivity, engagement effectiveness) but are often not independently validated and may omit baselines, methodology, or counterfactuals.
Based on the product positioning and life sciences enterprise motion:
Get a comprehensive analysis of Tact.ai including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →G2 shows a moderate number of reviews and a moderately positive overall rating for “Tact” by Tact.ai.
Positive themes (examples):
Negative themes (examples):
Important caveat about review recency: The surfaced G2 reviews in the accessible extracts skew toward older years, and the G2 profile indicates recent inactivity. That may indicate limited recent review volume, a product transition, or reduced review management—so readers should be cautious about assuming these reviews reflect the current (post-acquisition) state.
While not customer reviews, employee reviews can signal product stability and support quality.
More positive (Glassdoor):
More negative (Blind):
These are not direct product quality indicators, but they do raise continuity risk and potential support/roadmap uncertainty—especially around the acquisition timeframe.
A “Customer Success Report” PDF referencing Tact.ai exists (a dated AI sales-assistant compilation), but such compilations can be marketing-oriented aggregations rather than independent audits.
Critical evaluation:
Tact.ai is described as an AI-assisted customer engagement and field productivity platform focused on conversational and voice-driven workflows that integrate with systems such as Salesforce/CRM and common work tools (email/calendar). Public product descriptions emphasize a design oriented toward mobile devices, conversational inputs (voice/text), CRM data capture, and surfacing contextual account and contact information and activity logging. Sources describing the product in this way include G2’s product profile and press coverage describing Tact as a contextual layer on top of CRM intended to simplify CRM usage rather than replace it.
A material change for buyers: in November 2023, Aktana announced it acquired Tact.ai’s field engagement and conversational AI technology, and Aktana introduced "Aktana Copilot" using Tact.ai technology, targeting life sciences field users (sales representatives and MSLs). This acquisition affects Tact.ai’s current market identity compared with earlier years when it was marketed broadly as a sales assistant for CRM adoption.
Evidence: